Genix Pharmaceuticals Corporation

Equities

GENX

CA37232A1093

Food Processing

Delayed Toronto S.E. 11:14:16 09/05/2024 pm IST 5-day change 1st Jan Change
0.05 CAD +11.11% Intraday chart for Genix Pharmaceuticals Corporation +42.86% +150.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Genix Pharmaceuticals Corporation Reports Earnings Results for the First Quarter Ended January 31, 2024 CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Full Year Ended October 31, 2023 CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023 CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023 CI
Genix Pharmaceuticals Corporation Announces Board Changes CI
Genix Pharmaceuticals Corporation Auditor Raises 'Going Concern' Doubt CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Full Year Ended October 31, 2022 CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2022 CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2022 CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the First Quarter Ended January 31, 2022 CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Full Year Ended October 31, 2021 CI
Genix Pharmaceuticals Corporation Auditor Raises 'Going Concern' Doubt CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Third Quarter Ended July 31, 2021 CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Second Quarter Ended April 30, 2021 CI
Genix Pharmaceuticals : Starts Trading on OTCQB Venture Market Exchange MT
Genix Pharmaceuticals Corporation Appoints Mahmoud Aziz to the Board and as President CI
Genix Pharmaceuticals Corporation Enters into Exclusive License and Supply Agreement for First Generic Thyroid Medication CI
Genix Pharmaceuticals Corporation Prepares to File Abbreviated New Drug Submissions for its First Ten Ophthalmic Drugs with Health Canada CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Full Year Ended October 31, 2020 CI
Genix Pharmaceuticals Corporation Announces Executive Changes CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Third Quarter Ended July 31, 2020 CI
Genix Pharmaceuticals Corporation completed the acquisition of global distribution, sales and marketing rights and interest for Flu-X(r) from Canagen Pharmaceuticals Inc. CI
Genix Pharmaceuticals Corporation Elects Darryl Yea to the Board of Directors CI
Genix Pharmaceuticals Corporation Welcomes Monita Faris as Secretary CI
Genix Pharmaceuticals Corporation announced that it has received CAD 1.026734 million in funding CI
Chart Genix Pharmaceuticals Corporation
More charts
Genix Pharmaceuticals Corporation is a nutraceutical and generic ophthalmic drugs company. The Company is focused on the research, development, manufacturing, licensing, and sales of healthcare products. Its products include evidence-based, proprietary over the counter (OTC) nutraceuticals, and other single-molecule generic drugs. The Company is engaged in marketing and selling other nutraceuticals and some pharmaceutical products, such as bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, Lecithin softgels, fish oil softgels, EPO softgels and spirulina powder. Its products include Ketorolac 0.5% Eye Drops, Bimatoprost 0.01% Eye Drops, Timolol 0.5% Eye Drops, Loteprednol 0.5% Eye Drops, Diclofenac 0.1% Eye Drops, Brimonidine 0.2% Eye Drops. The Company sells its ophthalmic products through traditional pharmacy and drugstore retail outlets and as well as direct to consumers and e-commerce platforms.
More about the company
  1. Stock Market
  2. Equities
  3. GENX Stock
  4. News Genix Pharmaceuticals Corporation
  5. Genix Pharmaceuticals : Starts Trading on OTCQB Venture Market Exchange
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW